In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait

International Journal of Antimicrobial Agents

Volumn 20, Issue 4, 2002, Pages 270-274

  Jamal, Wafaa Y ^a   Mokaddas, Eiman M ^a   Verghese, Tina L ^a   Rotimi, V O ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Antibiotic susceptibility; Clinical isolates; Clostridium difficile

Indexed keywords

AMOXICILLIN; AMPICILLIN; CEFOTAXIME; CLAVULANIC ACID; CLINDAMYCIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN; TAZOBACTAM; TEICOPLANIN; TOXIN; TROVAFLOXACIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; IN VITRO STUDY; KUWAIT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TOXICITY;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, BACTERIAL; HUMANS; KUWAIT; MICROBIAL SENSITIVITY TESTS;

EID: 0036775812     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00180-2     Document Type: Article

References (35)

1. Bartlett J.G., Chang T.W., Gurwith M., Gorbach S.L., Onderdonk A.B. Antibiotic-associated colitis due to toxin producing clostridia. N. Engl. J. Med. 298:1978;531-534.
2. Gerding D.N., Johnson S., Peterson L.R., Mulligan M.E., Silva J. Jr. Clostridium difficile-associated diarrhea and colitis. Infect. Control Hosp. Epidemiol. 16:1995;459-477.
3. Wilcox M.H., Cunniffe J.G., Trundle C., Redbath C. Financial burden of hospital acquired Clostridium difficile infection. J. Hosp. Infect. 34:1996;23-30.
4. Spencer R.C. Clinical impact and associated costs of Clostridium difficile-associated disease. J. Antimicrob. Chemother. 41:1998;5-12.
5. Teasley D.G., Olson M.M., Gibhard R.L., et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet. 1:1983;1043-1046.
6. Wilcox M.H., Howe R. Diarrhoea caused by Clostridium difficile: response time with metronidazole and vancomycin. J. Clin. Microbiol. 36:1995;673-679.
7. Wenisch C., Parschalk B., Hasenhundi M., Hirschl A.M., Graninger W. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile-associated diarrhoea. Clin. Infect. Dis. 22:1996;813-818.
8. DeLalla F., Nicolin R., Rinaldi E., et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhoea. Antimicrob. Agents Chemother. 36:1992;2192-2196.
9. Goldstein E.J.C., Citron D.M. Susceptibility testing of anaerobes - fact, fancy and wishful thinking. Clin. Ther. 11:1989;710-723.
10. Wexler H.M. Susceptibility testing of anaerobic bacteria: myth, magic or method? Clin. Microbiol. Rev. 4:1991;470-484.
11. Reysset G., Huggond A., Sebald M. Genetics of 5-nitroimidazole resistance in Bacteroides. Clin. Infect. Dis. 16:(Suppl 4):1993;S401-S403.
12. Barbut F., Decre D., Burghoffer B., et al. Antimicrobial susceptibilities and serogroups of Clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob. Agents Chemother. 43:1999;2607-2611.
13. Rotimi V.O., Khoursheed M., Brazier J.S., Jamal W.Y. Bacteroides species highly resistant to metronidazole: an emerging clinical problem? Clin. Microbiol. Infect. 5:1999;166-169.
14. Jones R.N. Review of in vitro spectrum of activity of imipenem. Am. J. Med. 78:(Suppl 6A):1985;22-32.
15. Ueno K., Watanabe K., Bando K., Kato N. The antimicrobial susceptibility of recent clinical isolates of Bacteroides fragilis group. Clin. Infect. Dis. 6:(Suppl 4):1993;S382-S386.
16. Rotimi V.O., Mokaddas E.M., Jamal W.Y., Khodakhast F.B., Verghese T.L., Sanyal S.C. Susceptibility of 497 clinical isolates of Gram-negative anaerobes to trovafloxacin and eight other antibiotics. J. Chemother. 11:1999;349-356.
17. Pelaez T, Martinez-Sanchhez L, Alcala L, et al., Metronidazole Resistance in Clostridium Difficile: A New Emerging Problem? Abstract E-173, p.219. In programme and abstracts of the 38th Interscience Conference on Antimicrobial Chemotherapy. American Society for Microbiology, Washington, D.C. 1998.
18. National Committee of Clinical Microbiology Standards . Methods for antimicrobial susceptibility testing for anaerobic bacteria. Approved Standard M11-A4. 4th Ed. 1997;National Committee for Clinical Microbiology Standards, Wayne, Pa.
19. Mastoianni A., Coronado O., Nanetti, Valentini A., Manfredi R., Chiodo F. Nosocomial Clostridium difficile-associated diarrhoea in patients with AIDS: a three-year survey and review. CID. 25:(Suppl 2):1997;S204-S205.
20. Taylor M.E., Oppenheim B.A. Hospital-acquired infection in elderly patients. J. Hosp. Infect. 38:1998;245-260.
21. Chang T.W. Antibiotic-associated injury to the gut. Berk J.E., Bockus gastroenterology. 1985;2583-2592 WB Saunders, Philadelphia, PA.
22. Bartolini A., Colao M.G., Orsi A., Dei R., Giganti E., Parenti F. In vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MLD62873 and other agents against staphylococci, enterococci and Clostridium difficile. J. Antimicrob. Chemother. 26:1990;627-633.
23. Biavasco F., Manso E., Varaldo P.E. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 35:1991;195-197.
24. Gruer L. Susceptibility of Clostridium difficile strains to new antibiotics: quinolones, efrotomycin, teicoplanin and imipenem. J. Antimicrob. Chemother. 15:1985;648-649.
25. Nord C.E. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Clin. Infect. Dis. 23:(Suppl 1):1996;S15-S18.
26. Wong S.S., Woo P.C., Luk W., Yuen K. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diag. Microbiol. Infect. Dis. 34:1999;1-6.
27. Kelly C.P., Pothoulakins C., LaMont J.T. Clostridium difficile colitis. N. Engl. J. Med. 330:1994;257-262.
28. Olson M.M., Shanholtzer C.J., Lee Jr., Gerding D.N. Ten years of prospective Clostridium difficile associated-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect. Control. Hosp. Epidemiol. 15:1994;371-381.
29. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile associated diarrhoea and colitis. American College of Gastroenterology, Practice Parameter Committee. Am. J. Gastroenterol. 92:1997;739-750.
30. Wongwanich S., Kusum M., Phan-Urai R. Antibacterial activity of teicoplanin against Clostridium difficile. Southeast Asian J. Trop. Med. Public Health. 27:1996;606-609.
31. Chow A.W., Cheng N., Bartlett J.G. In vitro susceptibility of Clostridium difficile to new β-lactam and quinolone antibiotics. Antimicrob. Agents Chemother. 28:1985;842-844.
32. Goldstein E.J.C., Citron D.M., Warren Y., Tyrrell K., Merriam C.V. In vitro activity of gemifloxacin (SB 265805) against anaerobes. Antimicrob. Agents Chemother. 43:1999;2231-2235.
33. Levett P.N. Antimicrobial susceptibility of Clostridium difficile determined by disc diffusion and breakpoint method. J. Antimicrob. Chemother. 22:1988;167-173.
34. Johnson S., Samore M.H., Farrow K.A., et al. Epidemics of diarrhoea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N. Engl. J. Med. 341:1999;1645-1651.
35. Nelson D.E., Auerbach S.B., Baltch A.L., et al. Epidemic Clostridium difficile-associated diarrhoea: role of second- and third-generation cephalosporins. Infect. Control Hosp. Epidemiol. 15:1994;88-94.